A carregar...

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Xiang, Boyang, Zhao, Xiaoya, Zhou, Xiang
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8028072/
https://ncbi.nlm.nih.gov/pubmed/33827579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01266-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!